Pyrotinib-based therapeutic approaches for HER2-positive breast cancer: the time is now
Abstract Human epidermal growth factor receptor 2 (HER2)-positive breast cancer (BC) is a highly aggressive subtype associated with poor prognosis. The advent of HER2-targeted drugs, including monoclonal antibodies, tyrosine-kinase inhibitors (TKIs) and antibody–drug conjugates, has yielded improved...
| Main Authors: | , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
BMC
2023-10-01
|
| Series: | Breast Cancer Research |
| Subjects: | |
| Online Access: | https://doi.org/10.1186/s13058-023-01694-5 |
| _version_ | 1827707545304694784 |
|---|---|
| author | Xiaowei Qi Qiyun Shi Juncheng Xuhong Yi Zhang Jun Jiang |
| author_facet | Xiaowei Qi Qiyun Shi Juncheng Xuhong Yi Zhang Jun Jiang |
| author_sort | Xiaowei Qi |
| collection | DOAJ |
| description | Abstract Human epidermal growth factor receptor 2 (HER2)-positive breast cancer (BC) is a highly aggressive subtype associated with poor prognosis. The advent of HER2-targeted drugs, including monoclonal antibodies, tyrosine-kinase inhibitors (TKIs) and antibody–drug conjugates, has yielded improved prognosis for patients. Compared with widely used monoclonal antibodies, small-molecule TKIs have unique advantages including oral administration and favorable penetration of blood–brain barrier for brain metastatic BC, and reduced cardiotoxicity. Pyrotinib is an irreversible TKI of the pan-ErbB receptor, and has recently been shown to be clinically effective for the treatment of HER2-positive BC in metastatic and neoadjuvant settings. This review highlights the development on the application of pyrotinib-based therapeutic approaches in the clinical settings of HER2-positive BC. |
| first_indexed | 2024-03-10T16:49:05Z |
| format | Article |
| id | doaj.art-c29fc4d05fb3411cb15ea3610109f2ec |
| institution | Directory Open Access Journal |
| issn | 1465-542X |
| language | English |
| last_indexed | 2024-03-10T16:49:05Z |
| publishDate | 2023-10-01 |
| publisher | BMC |
| record_format | Article |
| series | Breast Cancer Research |
| spelling | doaj.art-c29fc4d05fb3411cb15ea3610109f2ec2023-11-20T11:22:01ZengBMCBreast Cancer Research1465-542X2023-10-0125111110.1186/s13058-023-01694-5Pyrotinib-based therapeutic approaches for HER2-positive breast cancer: the time is nowXiaowei Qi0Qiyun Shi1Juncheng Xuhong2Yi Zhang3Jun Jiang4Department of Breast and Thyroid Surgery, Southwest Hospital, Army Medical UniversityDepartment of Breast and Thyroid Surgery, Southwest Hospital, Army Medical UniversityDepartment of Breast and Thyroid Surgery, Southwest Hospital, Army Medical UniversityDepartment of Breast and Thyroid Surgery, Southwest Hospital, Army Medical UniversityDepartment of Breast and Thyroid Surgery, Southwest Hospital, Army Medical UniversityAbstract Human epidermal growth factor receptor 2 (HER2)-positive breast cancer (BC) is a highly aggressive subtype associated with poor prognosis. The advent of HER2-targeted drugs, including monoclonal antibodies, tyrosine-kinase inhibitors (TKIs) and antibody–drug conjugates, has yielded improved prognosis for patients. Compared with widely used monoclonal antibodies, small-molecule TKIs have unique advantages including oral administration and favorable penetration of blood–brain barrier for brain metastatic BC, and reduced cardiotoxicity. Pyrotinib is an irreversible TKI of the pan-ErbB receptor, and has recently been shown to be clinically effective for the treatment of HER2-positive BC in metastatic and neoadjuvant settings. This review highlights the development on the application of pyrotinib-based therapeutic approaches in the clinical settings of HER2-positive BC.https://doi.org/10.1186/s13058-023-01694-5PyrotinibHER-2 positiveBreast cancerTargeted therapyTyrosine-kinase inhibitor |
| spellingShingle | Xiaowei Qi Qiyun Shi Juncheng Xuhong Yi Zhang Jun Jiang Pyrotinib-based therapeutic approaches for HER2-positive breast cancer: the time is now Breast Cancer Research Pyrotinib HER-2 positive Breast cancer Targeted therapy Tyrosine-kinase inhibitor |
| title | Pyrotinib-based therapeutic approaches for HER2-positive breast cancer: the time is now |
| title_full | Pyrotinib-based therapeutic approaches for HER2-positive breast cancer: the time is now |
| title_fullStr | Pyrotinib-based therapeutic approaches for HER2-positive breast cancer: the time is now |
| title_full_unstemmed | Pyrotinib-based therapeutic approaches for HER2-positive breast cancer: the time is now |
| title_short | Pyrotinib-based therapeutic approaches for HER2-positive breast cancer: the time is now |
| title_sort | pyrotinib based therapeutic approaches for her2 positive breast cancer the time is now |
| topic | Pyrotinib HER-2 positive Breast cancer Targeted therapy Tyrosine-kinase inhibitor |
| url | https://doi.org/10.1186/s13058-023-01694-5 |
| work_keys_str_mv | AT xiaoweiqi pyrotinibbasedtherapeuticapproachesforher2positivebreastcancerthetimeisnow AT qiyunshi pyrotinibbasedtherapeuticapproachesforher2positivebreastcancerthetimeisnow AT junchengxuhong pyrotinibbasedtherapeuticapproachesforher2positivebreastcancerthetimeisnow AT yizhang pyrotinibbasedtherapeuticapproachesforher2positivebreastcancerthetimeisnow AT junjiang pyrotinibbasedtherapeuticapproachesforher2positivebreastcancerthetimeisnow |